Cargando…
The Therapeutic Potential of Novel Carnosine Formulations: Perspectives for Drug Development
Carnosine (beta-alanyl-L-histidine) is an endogenous dipeptide synthesized via the activity of the ATP-dependent enzyme carnosine synthetase 1 and can be found at a very high concentration in tissues with a high metabolic rate, including muscles (up to 20 mM) and brain (up to 5 mM). Because of its w...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10300694/ https://www.ncbi.nlm.nih.gov/pubmed/37375726 http://dx.doi.org/10.3390/ph16060778 |
_version_ | 1785064638620106752 |
---|---|
author | Bonaccorso, Angela Privitera, Anna Grasso, Margherita Salamone, Sonya Carbone, Claudia Pignatello, Rosario Musumeci, Teresa Caraci, Filippo Caruso, Giuseppe |
author_facet | Bonaccorso, Angela Privitera, Anna Grasso, Margherita Salamone, Sonya Carbone, Claudia Pignatello, Rosario Musumeci, Teresa Caraci, Filippo Caruso, Giuseppe |
author_sort | Bonaccorso, Angela |
collection | PubMed |
description | Carnosine (beta-alanyl-L-histidine) is an endogenous dipeptide synthesized via the activity of the ATP-dependent enzyme carnosine synthetase 1 and can be found at a very high concentration in tissues with a high metabolic rate, including muscles (up to 20 mM) and brain (up to 5 mM). Because of its well-demonstrated multimodal pharmacodynamic profile, which includes anti-aggregant, antioxidant, and anti-inflammatory activities, as well as its ability to modulate the energy metabolism status in immune cells, this dipeptide has been investigated in numerous experimental models of diseases, including Alzheimer’s disease, and at a clinical level. The main limit for the therapeutic use of carnosine is related to its rapid hydrolysis exerted by carnosinases, especially at the plasma level, reason why the development of new strategies, including the chemical modification of carnosine or its vehiculation into innovative drug delivery systems (DDS), aiming at increasing its bioavailability and/or at facilitating the site-specific transport to different tissues, is of utmost importance. In the present review, after a description of carnosine structure, biological activities, administration routes, and metabolism, we focused on different DDS, including vesicular systems and metallic nanoparticles, as well as on possible chemical derivatization strategies related to carnosine. In particular, a basic description of the DDS employed or the derivatization/conjugation applied to obtain carnosine formulations, followed by the possible mechanism of action, is given. To the best of our knowledge, this is the first review that includes all the new formulations of carnosine (DDS and derivatives), allowing a decrease or complete prevention of the hydrolysis of this dipeptide exerted by carnosinases, the simultaneous blood–brain barrier crossing, the maintenance or enhancement of carnosine biological activity, and the site-specific transport to different tissues, which then offers perspectives for the development of new drugs. |
format | Online Article Text |
id | pubmed-10300694 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-103006942023-06-29 The Therapeutic Potential of Novel Carnosine Formulations: Perspectives for Drug Development Bonaccorso, Angela Privitera, Anna Grasso, Margherita Salamone, Sonya Carbone, Claudia Pignatello, Rosario Musumeci, Teresa Caraci, Filippo Caruso, Giuseppe Pharmaceuticals (Basel) Review Carnosine (beta-alanyl-L-histidine) is an endogenous dipeptide synthesized via the activity of the ATP-dependent enzyme carnosine synthetase 1 and can be found at a very high concentration in tissues with a high metabolic rate, including muscles (up to 20 mM) and brain (up to 5 mM). Because of its well-demonstrated multimodal pharmacodynamic profile, which includes anti-aggregant, antioxidant, and anti-inflammatory activities, as well as its ability to modulate the energy metabolism status in immune cells, this dipeptide has been investigated in numerous experimental models of diseases, including Alzheimer’s disease, and at a clinical level. The main limit for the therapeutic use of carnosine is related to its rapid hydrolysis exerted by carnosinases, especially at the plasma level, reason why the development of new strategies, including the chemical modification of carnosine or its vehiculation into innovative drug delivery systems (DDS), aiming at increasing its bioavailability and/or at facilitating the site-specific transport to different tissues, is of utmost importance. In the present review, after a description of carnosine structure, biological activities, administration routes, and metabolism, we focused on different DDS, including vesicular systems and metallic nanoparticles, as well as on possible chemical derivatization strategies related to carnosine. In particular, a basic description of the DDS employed or the derivatization/conjugation applied to obtain carnosine formulations, followed by the possible mechanism of action, is given. To the best of our knowledge, this is the first review that includes all the new formulations of carnosine (DDS and derivatives), allowing a decrease or complete prevention of the hydrolysis of this dipeptide exerted by carnosinases, the simultaneous blood–brain barrier crossing, the maintenance or enhancement of carnosine biological activity, and the site-specific transport to different tissues, which then offers perspectives for the development of new drugs. MDPI 2023-05-23 /pmc/articles/PMC10300694/ /pubmed/37375726 http://dx.doi.org/10.3390/ph16060778 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Bonaccorso, Angela Privitera, Anna Grasso, Margherita Salamone, Sonya Carbone, Claudia Pignatello, Rosario Musumeci, Teresa Caraci, Filippo Caruso, Giuseppe The Therapeutic Potential of Novel Carnosine Formulations: Perspectives for Drug Development |
title | The Therapeutic Potential of Novel Carnosine Formulations: Perspectives for Drug Development |
title_full | The Therapeutic Potential of Novel Carnosine Formulations: Perspectives for Drug Development |
title_fullStr | The Therapeutic Potential of Novel Carnosine Formulations: Perspectives for Drug Development |
title_full_unstemmed | The Therapeutic Potential of Novel Carnosine Formulations: Perspectives for Drug Development |
title_short | The Therapeutic Potential of Novel Carnosine Formulations: Perspectives for Drug Development |
title_sort | therapeutic potential of novel carnosine formulations: perspectives for drug development |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10300694/ https://www.ncbi.nlm.nih.gov/pubmed/37375726 http://dx.doi.org/10.3390/ph16060778 |
work_keys_str_mv | AT bonaccorsoangela thetherapeuticpotentialofnovelcarnosineformulationsperspectivesfordrugdevelopment AT priviteraanna thetherapeuticpotentialofnovelcarnosineformulationsperspectivesfordrugdevelopment AT grassomargherita thetherapeuticpotentialofnovelcarnosineformulationsperspectivesfordrugdevelopment AT salamonesonya thetherapeuticpotentialofnovelcarnosineformulationsperspectivesfordrugdevelopment AT carboneclaudia thetherapeuticpotentialofnovelcarnosineformulationsperspectivesfordrugdevelopment AT pignatellorosario thetherapeuticpotentialofnovelcarnosineformulationsperspectivesfordrugdevelopment AT musumeciteresa thetherapeuticpotentialofnovelcarnosineformulationsperspectivesfordrugdevelopment AT caracifilippo thetherapeuticpotentialofnovelcarnosineformulationsperspectivesfordrugdevelopment AT carusogiuseppe thetherapeuticpotentialofnovelcarnosineformulationsperspectivesfordrugdevelopment AT bonaccorsoangela therapeuticpotentialofnovelcarnosineformulationsperspectivesfordrugdevelopment AT priviteraanna therapeuticpotentialofnovelcarnosineformulationsperspectivesfordrugdevelopment AT grassomargherita therapeuticpotentialofnovelcarnosineformulationsperspectivesfordrugdevelopment AT salamonesonya therapeuticpotentialofnovelcarnosineformulationsperspectivesfordrugdevelopment AT carboneclaudia therapeuticpotentialofnovelcarnosineformulationsperspectivesfordrugdevelopment AT pignatellorosario therapeuticpotentialofnovelcarnosineformulationsperspectivesfordrugdevelopment AT musumeciteresa therapeuticpotentialofnovelcarnosineformulationsperspectivesfordrugdevelopment AT caracifilippo therapeuticpotentialofnovelcarnosineformulationsperspectivesfordrugdevelopment AT carusogiuseppe therapeuticpotentialofnovelcarnosineformulationsperspectivesfordrugdevelopment |